Drugs / RGN-259
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT02597803 | Sep 2015 → Jun 2016 | dry eye syndrome | ReGenTree, LLC | Completed | Met primary |
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT05555589 | Apr 2023 → Apr 2026 overdue | neurotrophic keratopathy | ReGenTree, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03937882 | May 2019 → Nov 2020 | dry eye syndrome | ReGenTree, LLC | Completed | Missed primary |
| Phase 3 | NCT02974907 | Nov 2016 → Sep 2017 | dry eye syndrome | ReGenTree, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02600429 | Sep 2015 → Nov 2019 | neurotrophic keratopathy | ReGenTree, LLC | Terminated | Missed primary Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-05-06 | RegeneRx Biopharmaceuticals, Inc. | RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye regenerx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGN-259 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02600429 ↗ |
| Route | Topical | “A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days” NCT02597803 ↗ |